KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Assets (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Assets for 6 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 1.76% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Dec 2025, up 1.76%, and an annual FY2025 reading of $1.5 billion, up 1.76% over the prior year.
  • Assets was $1.5 billion for Q4 2025 at Recursion Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.5 billion in Q4 2025 and bottomed at $271.9 million in Q1 2021.
  • Average Assets over 5 years is $826.4 million, with a median of $685.6 million recorded in 2021.
  • The sharpest move saw Assets soared 170.03% in 2022, then dropped 14.56% in 2023.
  • Year by year, Assets stood at $610.3 million in 2021, then rose by 14.9% to $701.3 million in 2022, then fell by 6.79% to $653.7 million in 2023, then skyrocketed by 121.6% to $1.4 billion in 2024, then grew by 1.76% to $1.5 billion in 2025.
  • Business Quant data shows Assets for RXRX at $1.5 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.